Compare Diamondback Energy Inc (FANG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs BIO-TECHNE Corp — how do they compare? Diamondback Energy Inc trades at $192.13 (market cap $53.67B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Diamondback Energy Inc is far larger — about 4.7× BIO-TECHNE Corp's market cap, and Diamondback Energy Inc pays the higher dividend (2.3%). Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 69 Days and BIO-TECHNE Corp for 64 Days on average.
| FANG | TECH | |
|---|---|---|
Market Cap | $53.67B | $11.36B |
Volume | 2,250,644 | 5,390,331 |
Sector | Energy | Health |
52-Week High | $213.69 | $72.61 |
52-Week Low | $137.29 | $43.31 |
Typical Hold Time | 69 Days | 64 Days |
Enterprise Value | $65.83B | $11.39B |
Dividend Yield | 2.3% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $192.13, up 4.2% in the last session, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains solid cash flow from operations. Revenue growth is robust, with 2025 revenue reaching $14.93 billion, though net income margins have compressed. A dividend of $1.10 is scheduled for August 2026, and institutional interest remains high.
The outlook is positive with a consensus price target of $231.77, implying 20% upside. Risks include volatile oil prices and insider selling, but strong Permian Basin positioning and efficient operations support growth. Earnings on November 2, 2026, will be critical for near-term momentum.
TECH trades at $72.46, near its 52-week high of $72.70, with a slight daily decline of 0.1%. The stock shows a bullish technical signal from moving averages, while oscillators are neutral. Recent earnings have been mixed, with a Q2 2026 beat but a Q1 miss. The company maintains strong gross margins of 65.77%, though net income margin has compressed to 14.97% in 2025 from 24.6% in 2022. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The pending acquisition at $73.00 offers a clear near-term upside of about 0.7% from the current price, limiting downside risk. However, execution risks remain until deal closure, and profitability pressures pose concerns for standalone operations. Analyst consensus is divided with 46% Buy and 54% Hold ratings, reflecting cautious optimism amid transition uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
